BioWorld Asia

Jan. 9, 2008

Addex, Merck Ink $702M Deal for Schizophrenia Compound

Merck & Co. Inc. demonstrated its liking for Addex Pharmaceuticals AG's approach to modulating glutamate receptors by entering a second deal with the Swiss firm in consecutive months. (BioWorld International) Read More

NicOx Renews Research Deal with Pfizer in Ophthalmology

Gene Variant Could Provide Clues to the Cause of ALS

Silence Tries to Calm Investors After Share Price Takes a Dive

EMA Promises to Boost Professionalism in 2008

Faust Signs Research Deal with Takeda for GPCRs

Sepracor Enters $175M Deal with Bial for Epilepsy Drug

Biotech Industry Welcomes EU Support for its Products

Other News To Note

Financings Roundup

Today's news in brief

BioWorld

BioWorld briefs for March 6, 2026.

Microscopic image of clear cell carcinoma, the most common type of renal cell carcinoma.

Cas and effect: Merck’s phase III ripples HIF-2α space

BioWorld

Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...

News in brief

BioWorld Asia

BioWorld Asia briefs for March 3, 2026

Tanycytes in green capturing tau protein in red.

Brain’s hidden tau-clearing pathway uncovered

BioWorld Science

Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...

Muscarinic M4 receptor positive allosteric modulators described in Neurosterix patent

BioWorld Science

Neurosterix Pharma Sarl has divulged 3-cyclopropylpyrazole derivatives acting as muscarinic M4 receptor positive allosteric modulators. They are reported to be...